LEIDEN, The Netherlands– VarmX, a clinical-stage biotech company focusing on development of innovative approaches for the reversal of anticoagulation, today announced treatment of the first subjects in its first-in-human study for lead compound VMX-C001, and the transition of VarmX from a preclinical into a clinical company.
The two-part study is a randomised, double-blind, single ascending dose trial in healthy subjects. It will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenously administered VMX-C001, both alone and in combination with selected Direct Oral Anticoagulants (DOACs). It is anticipated that up to 88 participants will be enrolled.
In the US and Europe combined, more than 10 million patients take Factor Xa (FXa) DOACs long-term for the prevention of stroke and deep vein thrombosis. Each year, 2-3% of these patients experience spontaneous and severe bleeding as a side effect of DOAC use, and others need to undergo emergency surgery, which has an associated risk of bleeding.
VMX-C001 is able to rapidly and effectively restore coagulation in the presence of FXa DOACs. By doing so, the compound can facilitate treatment of severe bleeds and enable patients to undergo emergency surgery without the risk of bleeding associated with unopposed DOACs. VMX-C001 is expected to offer a number of benefits over existing treatments, including universal effectiveness against any FXa DOAC, ease of dosage and administration, absence of increased thrombotic risk, and the ability to use heparin if needed.
